New Molecular Classifications of Breast Cancer
New Molecular Classifications of Breast Cancer
复制标题
DOI：
10.3322/caac.20029
复制
发表时间：
2009-09-01
影响因子：
254.7
通讯作者：
Gradishar, William
中科院分区：
文献类型：
--
作者：
Cianfrocca, Mary;Gradishar, William
传统上，肿瘤大小、淋巴结状态、内分泌受体状态和人表皮生长因子受体2（HER 2）状态的病理学测定驱动了早期乳腺癌患者的预后预测和辅助治疗建议。然而，这些预后和预测因素是相对粗糙的措施，导致许多患者被过度治疗或治疗不足。因此，基因表达检测，有越来越多的认识，乳腺癌是一种分子异质性疾病。来自基因表达微阵列的证据表明存在多种分子亚型的乳腺癌。最近商业化的基因表达谱技术，预测疾病复发的风险，以及潜在的化疗的好处，在完善临床决策的承诺。这些技术将在这篇文章中进行审查。CA Cancer J Clin 2009;59：303-313. (C)2009年美国癌症协会，Inc。
Traditionally, pathologic determinations of tumor size, lymph node status, endocrine receptor status, and human epidermal growth factor receptor 2 (HER2) status have driven prognostic predictions and adjuvant therapy recommendations for patients with early stage breast cancer. However, these prognostic and predictive factors are relatively crude measures, resulting in many patients being overtreated or undertreated. As a result, of gene expression assays, there is growing recognition that breast cancer is a molecularly heterogeneous disease. Evidence from gene expression microarrays suggests the presence of multiple molecular subtypes of breast cancer. The recent commercial availability of gene expression profiling techniques that predict risk of disease recurrence as well as potential chemotherapy benefit have shown promise in refining clinical decision making. These techniques will be reviewed in this article. CA Cancer J Clin 2009;59:303-313. (C) 2009 American Cancer Society, Inc.